KaloBios (KBIO) Falls on NASDAQ Stock Delisting Notice

0
KaloBios (KBIO) Falls on NASDAQ Stock Delisting Notice
Chart via S&P Capital IQ

Shares of KaloBios Pharmaceuticals are trading lower today after the company received a delisting notice from NASDAQ due to its failure to satisfy the requirement for continued listing.

The stock price of the biopharmaceutical company declined more than 38% to $24.45 per share at the time of this writing.

KaloBios failed to file quarterly report on Form-Q

According to NASDAQ, KaloBios is currently not in compliance with its continued listing requirements due to its failure to submit its quarterly report on Form-Q for the quarter ended September 30, 2015, with the Securities and Exchange Commission (SEC).

Mohnish Pabrai On Waiting For The Perfect Pitch